These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37301185)

  • 1. Amelioratory effects of astragaloside IV on hepatocarcinogenesis via Nrf2-mediated pSmad3C/3L transformation.
    Fang Gong Y; Hou S; Xu JC; Chen Y; Zhu LL; Xu YY; Chen YQ; Li MM; Li LL; Yang JJ; Yang Y
    Phytomedicine; 2023 Aug; 117():154903. PubMed ID: 37301185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Astragaloside IV inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C/3L and Nrf2/HO-1 pathways.
    Zhang C; Li L; Hou S; Shi Z; Xu W; Wang Q; He Y; Gong Y; Fang Z; Yang Y
    J Ethnopharmacol; 2021 Oct; 279():114350. PubMed ID: 34157326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Astragaloside IV suppresses migration and invasion of TGF-β
    Li L; Wang Q; He Y; Sun L; Yang Y; Pang X
    Naunyn Schmiedebergs Arch Pharmacol; 2022 Apr; 395(4):397-405. PubMed ID: 35092472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nrf2 knockout attenuates the astragaloside IV therapeutic effect on kidney fibrosis from liver cancer by regulating pSmad3C/3L pathways.
    Wang Q; Xu J; Li M; Chen Y; Xu Y; Li L; Gong Y; Yang Y
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; 397(3):1687-1700. PubMed ID: 37712971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compound Astragalus and Salvia miltiorrhiza extract inhibits hepatocellular carcinoma progression via miR-145/miR-21 mediated Smad3 phosphorylation.
    Wu C; Chen W; Fang M; Boye A; Tao X; Xu Y; Hou S; Yang Y
    J Ethnopharmacol; 2019 Mar; 231():98-112. PubMed ID: 30412748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.
    Li Q; Liu G; Yuan H; Wang J; Guo Y; Chen T; Zhai R; Shao D; Ni W; Tai G
    Oncotarget; 2015 Feb; 6(6):4253-65. PubMed ID: 25714018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smad3 C-terminal phosphorylation site mutation attenuates the hepatoprotective effect of salvianolic acid B against hepatocarcinogenesis.
    Gong Y; Li D; Li L; Yang J; Ding H; Zhang C; Wen G; Wu C; Fang Z; Hou S; Yang Y
    Food Chem Toxicol; 2021 Jan; 147():111912. PubMed ID: 33290806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B.
    Murata M; Matsuzaki K; Yoshida K; Sekimoto G; Tahashi Y; Mori S; Uemura Y; Sakaida N; Fujisawa J; Seki T; Kobayashi K; Yokote K; Koike K; Okazaki K
    Hepatology; 2009 Apr; 49(4):1203-17. PubMed ID: 19263472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling.
    Liu R; Tang C; Shen A; Luo H; Wei X; Zheng D; Sun C; Li Z; Zhu D; Li T; Wu Z
    Oncotarget; 2016 Dec; 7(51):85079-85096. PubMed ID: 27835881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvianolic acid B exerts an anti-hepatocellular carcinoma effect by regulating the Hippo/YAP pathway and promoting pSmad3L to pSmad3C simultaneously.
    Xu W; Shi Z; Yu X; Xu Y; Chen Y; He Y; Gong Y; Huang C; Tan C; Yang Y
    Eur J Pharmacol; 2023 Jan; 939():175423. PubMed ID: 36509132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis.
    Kawamata S; Matsuzaki K; Murata M; Seki T; Matsuoka K; Iwao Y; Hibi T; Okazaki K
    Inflamm Bowel Dis; 2011 Mar; 17(3):683-95. PubMed ID: 20602465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma.
    Matsuzaki K; Murata M; Yoshida K; Sekimoto G; Uemura Y; Sakaida N; Kaibori M; Kamiyama Y; Nishizawa M; Fujisawa J; Okazaki K; Seki T
    Hepatology; 2007 Jul; 46(1):48-57. PubMed ID: 17596875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smad3 and its phosphoisoforms are prognostic predictors of hepatocellular carcinoma after curative hepatectomy.
    Kim SH; Ahn S; Park CK
    Hepatobiliary Pancreat Dis Int; 2012 Feb; 11(1):51-9. PubMed ID: 22251470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of microRNA-21/145 and Smad3 domain-specific phosphorylation in hepatocellular carcinoma.
    Wang JY; Fang M; Boye A; Wu C; Wu JJ; Ma Y; Hou S; Kan Y; Yang Y
    Oncotarget; 2017 Oct; 8(49):84958-84973. PubMed ID: 29156696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smad3 phosphoisoform-mediated signaling during sporadic human colorectal carcinogenesis.
    Matsuzaki K
    Histol Histopathol; 2006 Jun; 21(6):645-62. PubMed ID: 16528675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smad3 gene C-terminal phosphorylation site mutation exacerbates CCl
    Yang J; Gong Y; Xu W; Li L; Shi Z; Wang Q; He Y; Zhang C; Luo C; Fang Z; Yang Y
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Aug; 394(8):1779-1786. PubMed ID: 34191114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smad Phospho-Isoforms for Hepatocellular Carcinoma Risk Assessment in Patients with Nonalcoholic Steatohepatitis.
    Suwa K; Yamaguchi T; Yoshida K; Murata M; Ichimura M; Tsuneyama K; Seki T; Okazaki K
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31991602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compound Astragalus and Salvia miltiorrhiza extracts modulate MAPK-regulated TGF-β/Smad signaling in hepatocellular carcinoma by multi-target mechanism.
    Boye A; Wu C; Jiang Y; Wang J; Wu J; Yang X; Yang Y
    J Ethnopharmacol; 2015 Jul; 169():219-28. PubMed ID: 25934513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylated Smad2 and Smad3 signaling: Shifting between tumor suppression and fibro-carcinogenesis in chronic hepatitis C.
    Yamaguchi T; Matsuzaki K; Inokuchi R; Kawamura R; Yoshida K; Murata M; Fujisawa J; Fukushima N; Sata M; Kage M; Nakashima O; Tamori A; Kawada N; Tsuneyama K; Dooley S; Seki T; Okazaki K
    Hepatol Res; 2013 Dec; 43(12):1327-42. PubMed ID: 23458062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma.
    Murata M; Yoshida K; Yamaguchi T; Matsuzaki K
    World J Gastroenterol; 2014 Nov; 20(41):15018-27. PubMed ID: 25386050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.